Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0FZPDA
ADC Name
WO2018098269A2 conjugate 53B
Synonyms
WO2018098269A2_conjugate-53B
   Click to Show/Hide
Organization
Mersana Therapeutics, Inc.
Drug Status
Investigative
Indication
In total 3 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Gastric cancer [ICD11:2B72]
Investigative
Ovarian cancer [ICD11:2C73]
Investigative
Drug-to-Antibody Ratio
16.4
Antibody Name
XMT-1535
  Antibody Info 
Antigen Name
Sodium-dependent phosphate transport protein 2B (SLC34A2)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
WO2018098269A2_conjugate 53B linker
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0.01
nM
CVCL_0465
Ovarian serous adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.01 nM Positive HER2 expression (HER2+++/++)
Method Description
Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model Ovarian serous adenocarcinoma OVCAR-3 cells CVCL_0465
References
Ref 1 Peptide-containing linkers for antibody-drug conjugates.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.